Your search found 3 Results
Randomised study of effect of different doses of vitamin A on childhood morbidity and mortality. [Étude randomisée sur l'effet de différentes doses de vitamine A sur la morbidité et la mortalité infantiles]
BMJ. British Medical Journal. 2005 Dec 17; 331(7530):1428-1432.The objectives were to determine whether the dose of vitamin A currently recommended by the World Health Organization or half this dose gives better protection against childhood morbidity and mortality. Design: Randomised study. Setting: A combined oral polio vaccine and vitamin A supplementation campaign in Guinea-Bissau, Africa. Participants: 4983 children aged 6 months to 5 years. Interventions: One of two doses of vitamin A (recommended and half); oral polio vaccine. Main outcome measures: Mortality and morbidity at six and nine months. Mortality was lower in the children who took half the recommended dose of vitamin A compared with the full dose at both six months (mortality rate ratio 0.69, 95% confidence interval 0.36 to 1.35) and nine months (0.62, 0.36 to 1.06) of follow-up. There was a significant interaction between sex and dose, the lower dose being associated with significantly reduced mortality in girls (0.19, 0.06 to 0.66) but not in boys (1.98, 0.74 to 5.29). The lower dose of vitamin A was consistently associated with lower hospital case fatality in girls (0.19, 0.02 to 1.45). Paradoxically, in children aged 6-18 months, the low dose was associated with slightly higher morbidity. Half the dose of vitamin A currently recommended by WHO may provide equally good or better protection against mortality but not against morbidity. (author's)
[Tamoxifen or tamoxifen in combination with chemotherapy in adjuvant therapy of breast carcinoma. Results of a multicenter randomized study] Tamoxifen nebo tamoxifen v kombinaci s chemoterapií v adjuvantní lécbe karcinomu prsu. Vysledky multicentrické randomizované studie.
Sbornik Lékarsky. 2001; 102(1):65-76.Between April 1994 and May 1997 103 breast cancer patients (pts), pT1c-3a, pN0-1, M0, were randomised after surgery to adjuvant tamoxifen (20 mg per day) or to tamoxifen plus CMF (C 500 mg/m2, M 40 mg/m2 and F 600 mg/m2 on days 1st and 8th q 28 day) in 6 cycles. The median age (49-72 years, median 58), tumour size, number of involved lymphnodes (0-3), estrogens receptor status, grade (I-III) and type of operation were well balanced among the 50 pts on tamoxifen and the 53 pts on tamoxifen plus CMF pts, preferably postmenopausal. Results. Grade of toxicity according to WHO criteria was not higher than two in both arms. Toxicity both haematological and non-haematological was higher in the group treated with chemotherapy (0 vs 32 resp. 20%) except weight gain +5% (52% in both group). After median follow-up of 42 mos five recurrences in tamoxifen and seven in tamoxifen plus CMF pts were observed (p=NS). The projected 3-y DFS is 92% for tamoxifen and 88% for tamoxifen plus CMF (p=NS). The 3-y OS is 88% for tamoxifen and 80% for tamoxifen plus CMF pts (p=NS). Conclusions. Both regimens are equally effective with higher toxicity in the group with combined chemo- and hormonal therapy. (author's)
The safety and feasibility of female condom reuse: report of a WHO consultation, 28-29 January 2002, Geneva.
Geneva, Switzerland, WHO, 2002. , 15 p.According to the recommendations of the first consultation, this second meeting (January 2002) was planned to review the resulting data and to develop further guidance on the safety of reuse of the female condom. The specific objectives and anticipated outcomes of this second consultation were to: Review the results and evaluate the implications of the recently completed microbiology and structural integrity experiments and the human use study; Develop a protocol or set of instructions for disinfecting and cleaning used female condoms safely; Outline future research areas and related issues for programme managers to consider when determining the balance of risks and benefits of female condom reuse in various contexts and settings. (excerpt)